As of Q4'25, Pfizer's (PFE) P/E ratio stands at -21.47, reflecting a negative earnings environment at the latest data point. This follows a volatile pattern over the observed period from Q1'23 to Q4'25, with the P/E ratio swinging from a low of 7.44 in Q1'23 to a peak of 73.42 in Q4'23, then dropping sharply into negative territory in Q1'24 and Q2'24 before partially recovering to positive values through most of 2024 and 2025. The chart displays significant volatility, with notable inflection points including the dramatic spike in Q4'23 and subsequent plunge to -518.43 in Q1'24. After this trough, the P/E ratio rebounded to a high of 36.99 in Q3'24, then gradually declined to 13.09 by Q2'25 before turning negative again in Q4'25. This pattern suggests periods of earnings instability and market uncertainty, with the most recent negative P/E indicating potential losses or extraordinary items impacting profitability at the end of the period.